Cortecs International has launched Helisal One-Step, a new product that tests blood samples for the presence of the bacteria that causes gastritis and peptic ulcers. [31-Dec-1996]
Laporte has sold its European adhesives operation to Elf of France for about £100m. [27-Dec-1996]
Amersham International has acquired the radiopharmaceutical business of Sorin Diagnostics from Sorin Biomedica of Italy for an initial £4.3m. [24-Dec-1996]
Glaxo Wellcome has won approval to sell Imigram, the migraine drug, in inhaled form in 12 European countries. [19-Dec-1996]
Scotia has won FDA approval to start clinical trials for Foscan, a photodynamic cancer treatment. [17-Dec-1996]
Xenova has raised about £23m in a stock market placing in order to fund the development of its drugs that are in trials. [12-Dec-1996]
Cookson is to gradually withdraw from the manufacture and sale of industrial pigments, setting up licensing agreements with Hoechst and closing its plant in New Jersey. [12-Dec-1996]
Celltech expects to be transformed into a profitable pharmaceuticals company in 1998 with the launch of two septic shock treatments developed in conjunction with Bayer. [11-Dec-1996]
Yule Catto is acquiring PFW Aroma Chemicals in the Netherlands from Hercules of the US for £21m. [10-Dec-1996]
Scotia, the biotechnology company, has reported encouraging results for SC-101c, the treatment for severe weight loss in cancer. [07-Dec-1996]
Cantab Pharmaceuticals has been given FDA approval for human trials of its Disc (disabled, infective, single cycle) virus technology. [03-Dec-1996]
British Biotech has begun human trials of BB-2983, its arthritis drug, in association with Glaxo Wellcome. [29-Nov-1996]
British Biotech is preparing to launch its first product in 1998 - lexipafant, a treatment for acute pancreatic disease. [28-Nov-1996]
ICI is to acquire St Clair, the Canadian chain of 400 paint stores. [28-Nov-1996]
Glaxo Wellcome is acquiring full control of Nippon Glaxo, its joint venture with Shin Nihon Jitsugyo, for £360m. [22-Nov-1996]
Oxford Molecular has won a US patent on software that manages libraries of molecular shapes. [22-Nov-1996]
Chiroscience is acquiring Darwin Molecular, the US biotechnology company, for £72m, a move which will give it new skills in genomics and combinatorial chemistry. [21-Nov-1996]
Allied Colloids has acquired CPS, the US producer of water-soluble polymers, for £230m. [20-Nov-1996]
Laporte is to close offices in Luton and Bedford Square and set up its main corporate office in London. [20-Nov-1996]
Hickson International has sold its Hickson Manro business to Broomco, a new company that includes some managers from Manro, for £26.5m, as part of its debt reduction programme. [19-Nov-1996]
Vanguard Medica is to start the final stage of clinical testing for VML251, its migraine drug, and hopes to launch the product in 2000. [19-Nov-1996]
British Biotech is to receive up to £45m from Tanabe Seiyaku for the development and marketing of marimastat, its oral anti-cancer drug, in Japan. [15-Nov-1996]
Morgan Crucible has acquired EM Corporation, the lubricants supplier, from Great Lakes Chemical Corp for £16m. [14-Nov-1996]
Amersham International has signed a cross-licensing deal with Roche of Switzerland and Perkin-Elmer of the US, thus opening up the genetic research market to Amersham. [13-Nov-1996]
Glaxo Wellcome is to pay $72m to Ivax Corporation of the US for the right to use its breath-activated inhalation device. [12-Nov-1996]
BP Chemicals is planning a £528m petrochemical complex in Oman to produce 450,000 tonnes per year of ethylene and polyethylene, with start-up by 2000. [11-Nov-1996]
BTG has licensed an animal allergy vaccine to Peptide Therapeutics, who is in discussions with major companies about the commercialisation of the vaccine for use with pets. [05-Nov-1996]
Ellis & Everard has acquired Chemitrade, the Manchester-based distributor of solvents, for £7.4m. [05-Nov-1996]
Lawter International of the US is acquiring the resin division of Wolstenholme International for £5.5m. [04-Nov-1996]
Oxford Molecular is forming an alliance with Prolifix, the biotechnology company, in which Prolifix will fund research into drug development and pay royalty fees to Oxford Molecular for its drug design software. [01-Nov-1996]
BP Chemicals is to set up a joint venture with Shanghai Petrochemical to build a $2.5bn petrochemical complex in Shanghai, including a 650,000 tonnes per year ethylene cracker. [22-Oct-1996]
Pharmaceutical companies are expected to spend a record £2bn on research and development this year according to a report from the Centre for Medicines Research. [22-Oct-1996]
Shire Pharmaceuticals' Alzheimer's disease drug, Reminyl, is moving into the final stage of clinical trials in the US, through its partner Janssen Pharmaceutica. [22-Oct-1996]
Cortecs International has launched Clotam, the anti-migraine drug, into the UK under licence from Bristol-Myers Squibb. [22-Oct-1996]
Amersham International has spent £42m increasing its stake in Nihon Medi-Physics, its radiopharmaceutical joint venture with Sumitomo Chemical of Japan. [19-Oct-1996]
KS Biomedix has agreed a licensing deal with Hoffman-La Roche to develop a sheep monoclonal antibody. [15-Oct-1996]
Kalon, the paints company, has won approval from the courts to restructure its French operations with the loss of 100 jobs. [15-Oct-1996]
Shell and BASF are to merge their polyethylene businesses into a 50:50 joint venture in response to the industry's overcapacity and volatile prices. [11-Oct-1996]
Quintiles of the US is to acquire Innovex, the UK pharmaceutical industry consultancy, for £500m. [08-Oct-1996]
Chiroscience is planning 15 new clinical trials on its Levobupivacaine long-lasting local anaesthetic, and is seeking a partner to continue its development. [08-Oct-1996]
An explosion has hit the Albright & Wilson flame-retardant chemicals plant in Avonmouth, apparently due to sodium chlorite being discharged into a storage tank containing epichlorhydrin. [04-Oct-1996]
Shire Pharmaceuticals, the developer of prescription medicines, is in discussions to acquire two or three companies that could market its products. [28-Sep-1996]
Celltech has won a US patent for a technique to build new human antibodies, which it hopes will lead to a new stream of royalty income. [27-Sep-1996]
Xenova, the biotechnology company, is planning a £25m share offering next month in order to take its experimental drugs into the next development stage. [24-Sep-1996]
Blagden Industries is planning to spend £60m on acquisitions to develop its speciality chemicals business, particularly in the US and Europe. [20-Sep-1996]
English China Clays, the speciality chemicals and minerals concern, is planning a major restructuring which will include an overhaul of its manufacturing, distribution and research functions. [17-Sep-1996]
Astra of Sweden is to set up a £62m pharmaceuticals research centre in Loughborough, with the creation of about 200 new jobs. [10-Sep-1996]
BTR has sold its controlling stakes in three Taiwanese plastics joint ventures to a consortium comprising Union Petrochemical and USI Far East Corporation, for £191m. [10-Sep-1996]
Brunner Mond, the soda ash manufacturer, is planning a stock market listing in order to raise £46m for debt-reduction and the redemption of preference shares. [10-Sep-1996]
Oxford Biomedica, the gene-therapy concern, is planning a public share offer in November in order to raise £5m for the funding of a lease on a site in Oxford and the recruitment of up to 30 staff. [09-Sep-1996]
Vanguard Medica, the drug development concern, is to start developing compounds under licence for biotechnology companies. [06-Sep-1996]
Levington Horticulture, the fertiliser maker, is planning a £30m listing which will raise money to repay borrowings and to finance acquisitions. [02-Sep-1996]
ICI Surfactants Indonesia has opened a manufacturing plant near Jakarta. [29-Aug-1996]
BTG has signed a worldwide development and marketing deal with Forest Laboratories of the US for a new painkiller that combines oxycodone with ibuprofen. [29-Aug-1996]
Hickson & Welch has won a £1.5m DTI grant to expand its chemicals plant in Castleford. [28-Aug-1996]
ICI has dropped plans to build a titanium dioxide plant in China, following disagreements with its Chinese partner Yu Chang. [21-Aug-1996]
Plascon of South Africa is acquiring Courtaulds' Taubmans architectural coatings operation in Australia for £17m. [21-Aug-1996]
Hodgson Chemicals, the BTP subsidiary, has acquired ICI Surfactants' US-based textile operation for $2.3m. [14-Aug-1996]
ICI is selling Devoe's marine coatings business to Ameron International of California. [09-Aug-1996]
Glaxo has won European approval to sell its Epivir Aids drug, which could generate sales of up to $400m a year. [09-Aug-1996]
Cleveland Potash is seeking permission to extend its Boulby potash mine further underground towards Whitby, in order to secure the future of the mine for another ten years. [05-Aug-1996]
Brunner Mond, the soda ash maker, is planning a stock market listing in the autumn, in order to raise £60m. [05-Aug-1996]
Royal Dutch/Shell is looking to form an alliance with a producer of PTA, the raw material for PET, in order to boost its underperforming chemicals business. [02-Aug-1996]
European Colour is to buy Tor, the specialist coatings maker, for £13m. [01-Aug-1996]
Cambrio, the biotechnology concern, has abandoned plans for a flotation due to the recent poor performance of biotechnology shares. [31-Jul-1996]
Inspec is acquiring Shell's Fine Chemicals business for £200m, with the help of a £101m rights issue. [27-Jul-1996]
ICI is planning 2,700 job cuts, mainly in the US, as part of a productivity drive in response to tough market conditions. [26-Jul-1996]
Cortecs International has started trials of a bronchitis vaccine that is taken by mouth. [25-Jul-1996]
KS Biomedix has announced plans to start licensing its sheep monoclonal antibody technology to major drug companies within a year. [24-Jul-1996]
Reckitt & Colman has sold its 80% stake in Globo SA Tintas e Pigmentos, the Brazilian paints and coatings concern, to Bayer for £48m. [23-Jul-1996]
British Biotech has seen only about half its shareholders take up its £143m rights issue, in a further disappointment for the UK biotechnology sector. [18-Jul-1996]
Ellis & Everard is looking to acquire European polymer distribution businesses. [16-Jul-1996]
BOC is acquiring a controlling stake in the Volgograd Oxygen Factory in Russia. [16-Jul-1996]
Laporte has disposed of more non-core businesses for a total £23m, including the process chemicals business Gramos, the cleanroon garments operation Countdown Clean Systems, the US pet litter business Waverly Minerals, and its 50% stake in Laporte (Malaysia). [11-Jul-1996]
ML Laboratories has won approval from the Medicines Control Agency to use the salbutamol asthma drug in its dry powder inhaler. [10-Jul-1996]
SmithKline Beecham has won UK approval for ropinirole, the treatment for Parkinson's disease which will be sold under the ReQuip trade name. [09-Jul-1996]
Glaxo Wellcome has lost a court battle in North Carolina, which means that Novopharm of Canada will be able to start selling a generic version of Glaxo's Zantac anti-ulcer drug when the patent expires in July 1997. [08-Jul-1996]
Zeneca has won FDA approval to sell Kadian, a morphine-based pain relief drug, in capsule form in the US. [06-Jul-1996]
SmithKline Beecham is selling results of its gene research to Schering-Plough of the US and Synthelabo of France for $55m and $35m respectively. [03-Jul-1996]
Meconic is buying Phoenix Chemicals, the contract manufacturer, for up to £12m. [03-Jul-1996]
Glaxo Wellcome and Vertex of the US are acquiring non-exclusive worldwide rights to a GD Searle patent for $25m, which will enable them to work on the 141W94 anti-HIV drug. [02-Jul-1996]
The government has banned the use of Roseclear, Zeneca's garden pesticide, due to fears over potential eye damage. [28-Jun-1996]
British Biotech is planning a £143m rights issue to fund its development into a major international pharmaceutical group. [27-Jun-1996]
Chiroscience has launched its first product, an arthritis drug called dexketoprofen, in Spain. [27-Jun-1996]
Laporte, the chemicals company, has sold most of its Australasian operations to Fernz Corp of New Zealand for £29.5m. [27-Jun-1996]
Quintiles, the US pharmaceutical research company, is to set up a clinical data management service plant in West Lothian, creating up to 300 jobs. [25-Jun-1996]
BTP, the speciality chemicals company, is planning to make further substantial acquisitions, but is not considering any more disposals. [25-Jun-1996]
Cortecs, the biotechnology company, has signed a deal with two Danish organisations - Osteometer Biotech and the Centre for Clinical and Basic Research - concerning clinical trials on oral methods of taking insulin. [25-Jun-1996]
Alizyme, the biopharmaceutical company developing drugs for obesity, is planning a share placing on Aim next month in order to raise up to £15m. [25-Jun-1996]
Zeneca has won US approval to sell its new Merrem antibiotic, which works against a wide range of bacteria. [25-Jun-1996]
Zeneca has signed a deal with Incyte Pharmaceuticals of the US to give it access to genetics databases, at a cost of up to £7m a year. [18-Jun-1996]
Celltech is selling Celltech Biologicals to Alusuisse-Lonza of Switzerland for £50m. [13-Jun-1996]
Doeflex is acquiring BTP's industrial polymers operation for about £6m. [12-Jun-1996]
Appryl, the Elf-BP joint venture, is planning a £100m 300,000 tonnes per year polypropylene plant in Grangemouth, creating up to 200 jobs. [11-Jun-1996]
Oxford Molecular has announced a research deal with Alizyme in which they will develop compounds to treat obesity. [11-Jun-1996]
Glaxo Wellcome and SmithKline Beecham are to collaborate in the development of treatments for antibiotic-resistant germs. [07-Jun-1996]
Medeva is buying some former Fisons businesses from Rhone-Poulenc Rorer for £263m, including Rochester, which is made up of Fison's former US headquarters and ten branded drugs. [07-Jun-1996]
Cortecs International has raised £46m in an institutional share placing, and some of the proceeds will be used to show that its process that allows osteoporosis drugs to be taken orally can be adapted to work on other molecules. [05-Jun-1996]
Therapeutic Antibodies, the specialist in poison antidotes, is planning a flotation through a £30m institutional placing that will value it at £150m. [04-Jun-1996]
W Canning, the speciality chemicals concern, has bought Amco Sari, a company that sells combustion improvement additives in France, for £2.1m. [01-Jun-1996]
Cortecs International has won FDA clearance to market a diagnostic kit that detects the presence of a bug that causes peptic ulcers. [31-May-1996]
Ellis & Everard is acquiring Giltrain Plastics, the Yorkshire-based supplier of polymers, for £4.15m. [24-May-1996]
Centeon, the US-based joint venture between Hoechst and Rhone-Poulenc Rorer, is to buy Delta Biotechnology, the Nottingham-based maker of human proteins, from BOC for £30m. [21-May-1996]
Hanson, the industrial conglomerate planning a demerger, is to allocate most of its debt to the chemicals division, which will be renamed Millennium Chemicals. [17-May-1996]
Cantab Pharmaceuticals, the biotechnology concern, plans to raise £25m in a share placing to increase production capacity and speed up the development of at least one product. [15-May-1996]
BASF is buying Zeneca's textile colours operation for up to £150m, which includes sites in Ellesmere Port, Brazil and North Carolina. [09-May-1996]
Chiroscience has bought Resolution Chemicals' pilot-scale development centre from E Merck for £5.5m. [08-May-1996]
Huntsman of the US is still trying to buy BP's styrene and polystyrene business, which has plants in Wales and France. [07-May-1996]
SmithKline Beecham has had a set-back in its plans for the Coreg heart drug, as advisers to the US FDA have voted not to recommend its approval. [04-May-1996]
ICI has set up two new divisions - performance chemicals and polyester. [03-May-1996]
Vanguard Medica, the pharmaceutical development company, is to float with a value of £111m. [03-May-1996]
Hanson has sold its Seven Seas vitamin supplements business to Merck of Germany for £150m. [03-May-1996]
ICI is to shake up its top management by replacing up to 40 of its top 150 executives with external appointments. [01-May-1996]
Chiroscience has pulled out of a deal with Pharmacia & Upjohn that was to see them jointly develop Chiroscience's levobupivacaine long-lasting anaesthetic. [26-Apr-1996]
Amersham International is increasing its stake in Nihon Medi-Physics, its radiopharmaceutical joint venture with Sumitomo Chemical, from 20% to 50% in exchange for Y8.3bn plus the transfer of its Japanese healthcare to NMP. [25-Apr-1996]
Oxford Molecular, the drug design concern, is to undergo a three-year joint research programme with Yamanouchi Pharmaceutical of Japan. [19-Apr-1996]
Peptide Therapeutics expects to sign a licensing agreement with Mochida of Japan in which Mochida will test and sell Peptide products in return for royalty payments. [17-Apr-1996]
The chemical industry has continued to relocate outside the UK, with a 40% increase in UK chemical assets abroad between 1989 and 1994, and a fall in foreign chemical assets in the UK. [16-Apr-1996]
The UK chemical and pharmaceutical industries saw a 51% rise in productivity between 1990 and 1995, twice the level of many of their international competitors, according to a review by the Office of National Statistics. [11-Apr-1996]
Yule Catto, the chemicals and building products concern, is looking for acquisitions that complement its "products, market sectors or management terms". [11-Apr-1996]
Huntsman of the US is to more than double polystyrene production at its Carrington plant near Manchester, creating 30 jobs, as part of a major worldwide investment programme. [09-Apr-1996]
Hickson International, the speciality chemicals concern, says it will make a major disposal this year to cut debt. [03-Apr-1996]
Enron Europe has bought ICI's 50% share in their joint venture, Teesside Gas Transportation, for an undisclosed sum. [02-Apr-1996]
Scotia Holdings, the drug development concern, has raised £10.2m in the US for research funding. [02-Apr-1996]
Proteus International and ML Laboratories have agreed to co-operate in the development of a prostate and breast cancer treatment. [29-Mar-1996]
Universal Ceramic Materials is planning a share offer to raise £3.6m to expand its Humberside magnesia plant. [23-Mar-1996]
Cortecs International has granted Teva Pharmaceuticals of Israel a licence to sell an oral formulation of salmon calcitonin, a drug for osteoporosis. [22-Mar-1996]
Glaxo Wellcome has published results for trials of Valtrex which indicate that people who continue to take the herpes treatment reduce the risk of recurrence. [22-Mar-1996]
Blagden Industries is planning a £10m factory to supply formaldehyde to ICI's polyurethane plant in Rotterdam. [22-Mar-1996]
Manders, the coatings and inks concern, is looking for an inks acquisition and is also planning to start exporting to North America. [22-Mar-1996]
Stanford Rook Holdings is starting trials of its tuberculosis drug in London and South Africa and hopes to start marketing in 1998. [22-Mar-1996]
Brunner Mond, the soda ash maker, is considering a stock market flotation but will not make a final decision until it has finished building a combined heat and power plant at its Northwich site. [21-Mar-1996]
Vanguard Medica, the pharmaceutical development company, plans to raise about £30m in a flotation in May. [20-Mar-1996]
Albright & Wilson is to further rationalise its surfactants business with disposals and closures. [20-Mar-1996]
Elan of Ireland has announced a $600m merger with Athena Neurosciences, the Californian biotechnology concern. [19-Mar-1996]
Skyepharma plans to raise £140m on the market to acquire Jago Holdings, the Swiss drug delivery concern. [19-Mar-1996]
Cookson is buying Engineered Polymers Corp, the US maker of structural foam plastics and pallets, for £57m. [16-Mar-1996]
Phytopharm, the plant-based medicines concern, is to float in London next month to raise over £12m. [16-Mar-1996]
Holliday Chemical is now concentrating on three areas - pharmaceuticals and fine chemicals, colours, and inorganic chemicals - and has closed inefficient plants and cut staffing levels by 66. [13-Mar-1996]
Laporte, the speciality chemicals concern, plans to cut 40% of its Luton head office staff and to sell businesses worth about 10% of sales. [12-Mar-1996]
The merger of Swiss drugs companies, Ciba and Sandoz, could result in 600 job losses in the UK. [12-Mar-1996]
Johnson Matthey is opening a titanium sponge plant in Salt Lake City, Utah, as part of a three year $40m investment strategy for titanium. [11-Mar-1996]
Leading chemical industry executives have been lobbying the government to tone down its opposition to a single European currency as they fear that opting out would damage the competitiveness of UK industry. [08-Mar-1996]
Cookson is to further increase its product and geographical coverage with the announcement of over £100m worth of acquisitions over coming weeks. [08-Mar-1996]
Zeneca has sold its speciality inks business to Sun Chemical for £40m and is discussing the sale of its textile dyes operation. [08-Mar-1996]
Glaxo Wellcome may be about to give up its fight to keep patent protection for Zantac in the US until 2002, as non-branded competitors are likely to be launched in July 1997. [07-Mar-1996]
Inspec has acquired a polyimide fibres operation from Lenzing of Austria for £5.7m. [06-Mar-1996]
ICI is buying Bunge, the South American paints concern, for $390m, its first major acquisition in South America. [05-Mar-1996]
ICI is planning to make some acquisitions in Asia in order to boost its balance sheet as analysts have warned it may be vulnerable to a takeover. [04-Mar-1996]
SCM Chemicals has awarded Babcock International a contract for a £75m expansion of its chloride process titanium dioxide plant at Stallingborough. [04-Mar-1996]
Hickson International is about to sell its South African speciality chemicals operation to a local consortium. [02-Mar-1996]
ICI is selling the aerosol and cleaning products operations of the recently-acquired Grow Group to Sherwin-Williams of the US for at least £35m. [02-Mar-1996]
SmithKline Beecham is to restructure by cutting 400 jobs and closing 10% of its manufacturing sites, including a reduction in size at its Crawley plant, although it will increase the size of its plant in Worthing. [01-Mar-1996]
Medeva, the pharmaceuticals concern, is on the look-out for acquisitions having just arranged a £125m five-year credit facility. [01-Mar-1996]
Glaxo Wellcome has rationalised its Italian facilities with a management buy-out at its Pomezia plant. [01-Mar-1996]
Scotia has ended a marketing arrangement with Pharmacia of Sweden which leaves it without a partner for Tarabetic, the diabetes drug. [27-Feb-1996]
Cookson Matthey Ceramics plans to spend £8m on two factories in Malaysia and India to make zircon opacifier. [23-Feb-1996]
Cortecs International has announced an agreement with Osteometer BioTech and the Centre for Clinical Basic Research, both of Denmark, to jointly develop an oral version of testosterone for male HRT. [23-Feb-1996]
Shell Chemicals plans to link up with BASF to build a plant in either the Netherlands or Germany to produce 250,000 tonnes a year of polypropylene and 550,000 tonnes a year of styrene monomer. [22-Feb-1996]
SmithKline Beecham is making a £250m provision to cover two disputes in the US - one concerning antitrust pricing and the other for alleged false claims for payment from the Medicare and Medicaid health service schemes. [21-Feb-1996]
Courtaulds is investing £120m to double output of Tencel, the wood-pulp based fabric, at its Grimsby plant. [21-Feb-1996]
Pharmacia & Upjohn is to close its Crawley plant, with the loss of about 200 jobs. [17-Feb-1996]
Amersham International has won FDA approval for its heart imaging drug called Myoview. [13-Feb-1996]
Glaxo Wellcome is to sell its 311C90 migraine drug to Zeneca to comply with competition requirements following the creation of the merged group. [09-Feb-1996]
Scotia's Swedish operation has granted Astra the right to use some of its specialist lipids in return for future royalties from resulting products. [09-Feb-1996]
Morgan Crucible has bought a 80% stake in Magna Industrial Company, the Hong Kong-based speciality chemicals concern. [08-Feb-1996]
Klinge Pharma has bought Ribosepharm, Medeva's cancer products business in Germany, for £54m. [07-Feb-1996]
Inspec has acquired a speciality chemical company in the US with plants in Arizona and Kansas, for $29m from Allied Signal. [07-Feb-1996]
ICI is planning a £60m expansion of its Dumfries polyester film plant, where it will be able to produce 20,000 tonnes a year with the main market being the packaging industry. [02-Feb-1996]
Celltech has abandoned research on an asthma drug, codenamed CDP840, which was expected to be a major earner for the company. [02-Feb-1996]
Harrisons & Crosfield has acquired Daniel Products, the US maker of chemicals for coatings, for $30m. [02-Feb-1996]
Shire Pharmaceuticals Group expects to raise £35m from a flotation and will use £20m on development. [26-Jan-1996]
ML Laboratories plans an institutional placing to generate £25m for development. [26-Jan-1996]
Shire Pharmaceuticals Group is to develop and market galanthamine, the Alzheimer's treatment, in a deal with Johnson & Johnson's Belgian operation, Janssen Pharmaceutics. [25-Jan-1996]
Rhone-Poulenc Rorer is cutting 140 sales and marketing jobs at its Eastbourne and Loughborough sites, in a rationalisation following its acquisition of Fisons. [24-Jan-1996]
Zeneca is planning a major restructuring of its manufacturing and distribution, but job losses are unlikely to hit R&D. [24-Jan-1996]
Therexsys plans to raise up to £10m in a private placement and expects to launch its first gene-therapy products by 2002. [24-Jan-1996]
Lawrence has disposed of over half its stake in Amberley Group, the minerals and speciality chemicals company, raising £1m. [24-Jan-1996]
Chiroscience has reported good final test results for its levobupivacaine local anaesthetic. [20-Jan-1996]
ICI Explosives is acquiring a 51% stake in Ibernobel of Spain. [13-Jan-1996]
Elan of Ireland has won FDA approval for Naprelan, the anti-arthritis drug it developed with Wyeth Ayerst Laboratories. [10-Jan-1996]
Ellis & Everard has acquired George Mann, the US distributor of caustic soda, bleach and chlorine, and Surphos Chemicals, the Benelux surfactants and phosphates distributor. [09-Jan-1996]
Brent Chemicals has sold its industrial chemicals activities in Asia to Chemetall, as part of its simplification programme. [05-Jan-1996]
BTR has sold its minority stake in Titan, the Malaysian petrochemical concern, for £89m. [03-Jan-1996]
Hickson International has sold Hickson Kerley, the US performance chemical operation, to Tessenderlo of Belgium. [03-Jan-1996]